Company intelligence / Profile preview
ARIZ Precision Medicine
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
Overview
ARIZ Precision Medicine is developing a platform that uses nanotechnology to deliver siRNA and chemotherapy directly into cancer cells by targeting the PRDM gene family. Proof-of-principle studies have shown selective killing of multiple types of cancer cells in vitro. The company is advancing its lead candidate into animal models with plans for an IND submission focused on lung cancers with altered PRDM genes. No clinical results in humans have been reported yet.[3][6][9]
- Therapeutic areas
- Oncology
- Modalities
- siRNA (small interfering RNA)Nanoparticle drug deliveryChemotherapy agents (encapsulated)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ARIZ Precision Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARIZ Precision Medicine.